US › Healthcare

AC Immune Ltd (ACIU)

US · Healthcare · Biotechnology

$2.27+2.25%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.1M
Revenue YoY
+13.0%
Net profit
$-14.8M
Profit YoY
+22.2%
EPS
$-0.15
EPS estimate
$-0.14
Net margin
-1,322.7%

EPS came in at -0.15 against a street estimate of -0.14 — a miss of 7.1%.

Key statistics

Market cap
$222.9M
Forward P/E
11.2
P/B
5.78
Book value
$0.40
EPS (TTM)
$-0.82
52-week high
$4.00
52-week low
$2.03
50-day MA
$2.43
200-day MA
$2.91
Beta
1.57

Analyst view

Analysts rate AC Immune Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.60.

Shareholding

Insiders
37.90%
Institutions
24.83%

Largest institutional holders

FundStake
Bvf Inc19.48%
Wells Fargo & Co0.99%
Millennium Management LLC0.78%
Renaissance Technologies Corp0.61%
BlackRock Inc0.52%
Arrowstreet Capital Limited Partnership0.40%
Dimensional Fund Advisors, Inc.0.38%
Northern Trust Corp0.27%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AC Immune Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.